- Home
- BYSI vs HLVX Comparison
BYSI vs HLVX Comparison
Compare BYSI & HLVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BYSI
- HLVX
- Stock Information
- Founded
- BYSI 2010
- HLVX 2020
- Country
- BYSI United States
- HLVX United States
- Employees
- BYSI N/A
- HLVX N/A
- Industry
- BYSI Biotechnology: Pharmaceutical Preparations
- HLVX Biotechnology: Pharmaceutical Preparations
- Sector
- BYSI Health Care
- HLVX Health Care
- Exchange
- BYSI Nasdaq
- HLVX Nasdaq
- Market Cap
- BYSI 71.0M
- HLVX 83.7M
- IPO Year
- BYSI 2017
- HLVX 2022
- Fundamental
- Price
- BYSI $2.28
- HLVX $2.07
- Analyst Decision
- BYSI
- HLVX Hold
- Analyst Count
- BYSI 0
- HLVX 5
- Target Price
- BYSI N/A
- HLVX $2.33
- AVG Volume (30 Days)
- BYSI 154.5K
- HLVX 451.9K
- Earning Date
- BYSI 08-11-2025
- HLVX 08-07-2025
- Dividend Yield
- BYSI N/A
- HLVX N/A
- EPS Growth
- BYSI N/A
- HLVX N/A
- EPS
- BYSI N/A
- HLVX N/A
- Revenue
- BYSI N/A
- HLVX N/A
- Revenue This Year
- BYSI N/A
- HLVX N/A
- Revenue Next Year
- BYSI N/A
- HLVX N/A
- P/E Ratio
- BYSI N/A
- HLVX N/A
- Revenue Growth
- BYSI N/A
- HLVX N/A
- 52 Week Low
- BYSI $0.98
- HLVX $1.34
- 52 Week High
- BYSI $3.44
- HLVX $2.35
- Technical
- Relative Strength Index (RSI)
- BYSI 47.79
- HLVX 64.33
- Support Level
- BYSI $2.21
- HLVX $1.99
- Resistance Level
- BYSI $2.50
- HLVX $2.12
- Average True Range (ATR)
- BYSI 0.30
- HLVX 0.08
- MACD
- BYSI -0.09
- HLVX 0.02
- Stochastic Oscillator
- BYSI 4.88
- HLVX 86.89
About BYSI BeyondSpring Inc.
BeyondSpring Inc is engaged in clinical-stage biopharmaceutical activities focused on the development of cancer therapies. It is also focused on including immuno-oncology agents. It operates in Plinabulin pipeline segment.
About HLVX HilleVax Inc.
HilleVax Inc is a clinical-stage biopharmaceutical company. The company is focused on developing and commercializing novel vaccines. The firm's initial program, HIL-214, is a virus-like particle (VLP) based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis (AGE) caused by norovirus infection.